The Nf-L changes observed in serum and CSF following ETV:IDS treatment suggest that serum Nf-L may be used as a treatment-responsive biomarker of neurodegeneration, as has been demonstrated for other neurodegenerative disorders like Batten’s disease (20) and spinal muscular atrophy (21). Here, NEFL is linked to spinal muscular atrophy.